Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

K ReichP RichC MaariRobert BissonnetteC LeonardiA MenterA IgarashiP KlekotkaD PatelJ LiJ TuttleM Morgan-CoxEmily Edson-HerediaS FriedrichKim A Pappnull null

Published in: The British journal of dermatology (2019)

At week 16, 67% of patients treated with mirikizumab 300 mg at 8-week intervals achieved PASI 90. The percentage of patients reporting at least one treatment-emergent adverse event was similar among patients treated with placebo or mirikizumab.

Keyphrases

phase ii study
end stage renal disease
newly diagnosed
open label
emergency department
early onset
peritoneal dialysis
radiation therapy
prognostic factors
combination therapy
locally advanced
patient reported outcomes
atopic dermatitis
electronic health record